Recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 Conditions Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States Anchorage Associates in Radiation Medicine — Anchorage, Alaska, United States Anchorage Radiation Therapy Center — Anchorage, Alaska, United States Alaska Breast Care and Surgery LLC — Anchorage, Alaska, United States View all 582 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors NCT02496208 Conditions Adenocarcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, +54 more Locations City of Hope Comprehensive Cancer Center — Duarte, California, United States Los Angeles General Medical Center — Los Angeles, California, United States USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States University of California Davis Comprehensive Cancer Center — Sacramento, California, United States View more locations Show fewer locations Loading locations... View Trial Details
